Cereno Scientific obtains patent protection in major market Japan for Phase II drug candidate CS1
Cereno Scientific today announced that drug candidate CS1 has obtained strengthened intellectual property rights (IPR) in Japan, one of the world’s largest pharmaceutical markets. The patent protection for CS1’s second patent family now covers key markets with previously granted markets, the US and Russia, as well as Japan. This adds to the growing portfolio of issued patents secured for Cereno’s assets to strengthen the commercial positioning.
“Japan is one of the world’s largest pharmaceutical markets, only behind the US and marginally China. The patent protection for CS1 now covering two of the major global markets is an attractive IPR position ahead of future developments”, says Sten R. Sörensen, CEO at Cereno Scientific.
The patent issued in Japan is part of Cereno’s second patent family associated with drug candidate CS1. The patent is titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation,” with patent number JP6787901. The patent will be valid through 2035, with the possibility of a patent extension of additional five years maximum.
Preparations for a Phase II study with drug candidate CS1 for the rare disease pulmonary arterial hypertension (PAH) is currently underway. A letter of intent (LOI) with the contract research organization (CRO) Worldwide Clinical Trials is signed and the collaboration started in January. The study is expected to be initiated in mid-2021.
For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87
Email: info@cerenoscientific.com
www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has the US subsidiary Cereno Scientific Inc. with an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.